Ignite Creation Date:
2025-12-24 @ 3:17 PM
Ignite Modification Date:
2026-04-16 @ 1:07 PM
Study NCT ID:
NCT02406092
Status:
COMPLETED
Last Update Posted:
2024-11-21
First Post:
2015-03-23
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
Sponsor:
Hoffmann-La Roche
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-10-13
Start Date Type:
ACTUAL
Primary Completion Date:
2021-06-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-06-30
Completion Date Type:
ACTUAL
First Submit Date:
2015-03-23
First Submit QC Date:
None
Study First Post Date:
2015-04-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2022-06-14
Results First Submit QC Date:
None
Results First Post Date:
2024-11-21
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-14
Last Update Post Date:
2024-11-21
Last Update Post Date Type:
ACTUAL